8-K: Context Therapeutics Acquires Phase 1-Ready T Cell Engager CT-95, Expanding Solid Tumor Pipeline

Context Therapeutics has acquired CT-95, a mesothelin x CD3 bispecific antibody, from Link Immunotherapeutics, adding a second clinical-stage T cell engager to its pipeline.

Summary

• Context Therapeutics acquired CT-95, a mesothelin x CD3 T cell engaging bispecific antibody, from Link (assignment for the benefit of creditors), LLC for $3.75 million.
• The acquisition includes patent rights, know-how, regulatory filings, and drug substance and product inventory.
• The U.S. Food and Drug Administration has already cleared the investigational new drug (IND) application for CT-95.
• Context Therapeutics plans to initiate a Phase 1 trial for CT-95 in the first quarter of 2025.
• The company intends to fund the acquisition and the dose escalation portion of the Phase 1 trial with existing cash.
• CT-95 is designed to target mesothelin, a protein overexpressed in several cancers, while minimizing the impact of shed mesothelin.
• The company also updated its corporate presentation for use in meetings with investors and analysts.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strategic acquisition of a promising asset, the planned clinical trial, and the company's strong financial position. The focus on innovation and addressing unmet needs in solid tumor treatment is also encouraging.

Positives

• The acquisition of CT-95 adds a promising asset to Context Therapeutics' pipeline.
• CT-95 has already received IND clearance, accelerating its path to clinical trials.
• The company has sufficient existing cash to fund the acquisition and initial clinical development.
• CT-95's design aims to overcome challenges associated with shed mesothelin, potentially improving efficacy.
• The company has a strong financial position with a high-quality investor base.
• The company anticipates a cash runway into 2028.

Negatives

• The acquisition of CT-95 involved a one-time payment of $3.75 million, which is a cash outflow for the company.
• The company is relying on existing cash to fund the acquisition and initial clinical trials, which may limit future flexibility.
• The company is assuming certain liabilities related to the acquired assets.
• The asset was acquired on an 'as is' and 'where is' basis, with limited warranties from the seller.

Risks

• The company's ability to successfully develop and commercialize CT-95 is subject to risks and uncertainties.
• Clinical trials may not produce the desired results, and regulatory approvals may not be granted.
• The company's financial resources may not be sufficient to complete the development of CT-95.
• There are risks associated with the manufacturing and supply of the drug product.
• The company faces competition from other companies developing similar therapies.
• The company is subject to reporting obligations under the Securities Act of 1933 and the Securities Exchange Act of 1934.

Future Outlook

Context Therapeutics expects to rapidly progress CT-95 into clinical trials, with a Phase 1 trial initiation planned for the first quarter of 2025, and intends to fund the acquisition and initial clinical development with existing cash.

Management Comments

• Martin Lehr, CEO of Context, stated that the acquisition of CT-95 is consistent with the company's focus on building a pipeline of TCE assets to treat solid tumors.
• Mr. Lehr also mentioned that they believe CT-95 has the potential to be both a first-in-class and best-in-class MSLN-targeting TCE.

Industry Context

The acquisition of CT-95 aligns with the growing interest in T cell engager therapies for solid tumors, as evidenced by recent clinical data showing promising efficacy and safety across various targets. This move positions Context Therapeutics to compete in the rapidly evolving field of cancer immunotherapy.

Comparison to Industry Standards

• The document mentions several competitors in the T cell engager space, including Amgen, Xencor, and Harpoon Therapeutics.
• CTIM-76 is compared to other CLDN6 x CD3 bispecifics, highlighting its high selectivity for CLDN6 over other claudin family members.
• CT-95 is positioned as a second-generation MSLN-targeting therapy, designed to overcome the limitations of first-generation approaches like HPN-536, which suffered from poor drug exposure due to binding to shed MSLN and albumin.
• The document notes that AbbVie's MSLN-targeting therapy, ABBV-428, had a 0% overall response rate at the highest dose tested.

Stakeholder Impact

• Shareholders may view the acquisition of CT-95 positively, as it expands the company's pipeline and potential for future growth.
• Employees may be impacted by the increased workload and responsibilities associated with the development of CT-95.
• Patients with solid tumors may benefit from the development of new and effective therapies.
• The acquisition may impact suppliers and partners involved in the development and manufacturing of CT-95.

Next Steps

• Initiate a Phase 1 clinical trial for CT-95 in the first quarter of 2025.
• Advance CTIM-76 into clinical trials with first patient dosing expected mid-2024.
• Continue to develop and evaluate the potential of both CTIM-76 and CT-95.

Key Dates

Keywords

T cell engager, bispecific antibody, CT-95, mesothelin, solid tumors, clinical trial, IND, oncology, CTIM-76, Claudin 6